Phylogica is pleased to announce that it has received firm commitments to raise $9.12 m (before costs) through a placement of shares to both new and existing sophisticated and institutional investors at a price of 3 cents per new security.
Use of funds
The successful completion of proof of concept work in 2018 sets Phylogica on the path to clinical (human) validation of its platform. Phylogica will use the funds raised to accelerate its path towards first in human trials of its Cell Penetrating Peptides (CPPs).
For further information please download PDF attached:
Download this document
